Clinical trials: Psilocybin
Posttraumatic Stress Disorder
Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)
The purpose of this study is to assess the safety and effectiveness of co-administered MDMA and psilocybin in military Veterans with a diagnosis of Posttraumatic Stress Disorder (PTSD).
- Trial name
- PAM-VET (NCT06989957)
- Testing
- Psilocybin, MDMA
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
PTSD
Psilocybin-Assisted Therapy
This pilot study will examine the safety, tolerability, acceptability, and efficacy of combination psilocybin + psychotherapy to decrease PTSD symptoms.
- Trial name
- NCT07332143
- Testing
- psilocybin, Supportive Therapy, Prolonged Exposure Therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Emory University
Major Depression
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S.
- Trial name
- PIVOT (NCT07226232)
- Testing
- Psilocybin
- Where
- 5 sites in United States
- Volunteers
- 240 people
- Sponsor
- VA Office of Research and Development
Depressive Disorder, Major
A Study of Psilocybin for Major Depressive Disorder (MDD)
One hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation…
- Trial name
- NCT03866174
- Testing
- Psilocybin, Niacin, Set and Setting (SaS) Protocol
- Where
- 11 sites in United States
- Volunteers
- 347 people
- Sponsor
- Usona Institute
Alcohol Use Disorder
Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder
This pilot study will collect preliminary data that measures the effects of psilocybin-assisted psychotherapy vs ketamine-assisted psychotherapy on patients struggling with alcohol use.
- Trial name
- NCT05421065
- Testing
- Psilocybin, Ketamine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Peggy C Nopoulos
Depressive Disorder, Major Depressive Disorder
A Randomized Neuroimaging Trial of Psilocybin in Depression
The goal of this neuroimaging clinical trial is to test whether psilocybin produces significant immediate changes in functional brain activity in networks associated with mood regulation and depression compared to placebo in…
- Trial name
- EMBRACE (NCT06072898)
- Testing
- Psilocybin, Microcrystalline cellulose, Supportive psychotherapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Sunnybrook Health Sciences Centre
Healthy Volunteers
Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers
The goal of this open-label, dose-escalation, prospective study is to evaluate the safety and psychological effects of a Psilocybin and D-Serine formulation in healthy volunteers. The main objectives are: 1.
- Trial name
- NCT07079930
- Testing
- Psilocybin and D-Serine, Physical Examination, Vital signs
- Where
- Israel
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Major Depressive Disorder
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.
- Trial name
- NCT05733546
- Testing
- Psilocybin
- Where
- 5 sites in United States
- Volunteers
- 102 people
- Sponsor
- COMPASS Pathways
Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
This phase I/II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of patients with metastatic cancer and symptoms of anxiety and/or depression.
- Trial name
- NCT05847686
- Testing
- Counseling, Psilocybin, Questionnaire Administration
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Washington
Major Depressive Disorder
Effects of Psilocybin in Major Depressive Disorder
The proposed pilot study will assess whether people with major depressive disorder experience psychological and behavioral benefits and/or harms from psilocybin.
- Trial name
- NCT03181529
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Johns Hopkins University
Methamphetamine Use Disorder
Psilocybin for Methamphetamine Addiction
The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana.
- Trial name
- NCT06899594
- Testing
- Psilocybin 25 mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kevin Murnane
Opioid Use Disorder
Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use
This study will investigate whether psilocybin administered under supportive conditions can reduce illicit opioid use and improve quality of life in individuals with Opioid Use Disorder (OUD) in Methadone Maintenance Treatment…
- Trial name
- NCT05242029
- Testing
- Psilocybin
- Sponsor
- Johns Hopkins University
Burnout, Caregiver, Burnout, Professional
Frontline Clinician Psilocybin Study
This study aims to investigate the effects of a single dose of psilocybin, delivered in the contextof pre- and post-dose psychotherapy, on symptoms of depression and burnout suffered by healthcare clinicians as a result of…
- Conditions
- Burnout, Caregiver, Burnout, Professional, COVID-19, Depression
- Trial name
- NCT05163496
- Testing
- Psilocybin (Usona Institute)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Disorders of Consciousness, Psychedelic Experiences
The Effects of Psilocybin on Shared Experience in Film Processing
The goal of this clinical trial is to learn whether certain methods of detecting awareness in vegetative or minimally conscious patients (using neuroimaging) are sensitive to the effects of psilocybin (a psychedelic drug).
- Trial name
- NCT06529939
- Testing
- Psilocybin
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Western University, Canada
Depressive Disorder, Major
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the selective serotonin reuptake inhibitor…
- Trial name
- Psilodep-RCT (NCT03429075)
- Testing
- Psilocybin + Escitalopram
- Where
- United Kingdom
- Volunteers
- 59 people
- Sponsor
- Imperial College London
Stuttering
Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter
This Phase 2a clinical trial is an open-label, single-group, within-subjects pilot study designed to evaluate the safety, feasibility, and preliminary efficacy of psilocybin as a therapeutic intervention for adults with…
- Trial name
- NCT07296328
- Testing
- Psilocybin, Speech therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
Parkinson Disease, Depression
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
- Conditions
- Parkinson Disease, Depression, Anxiety
- Trial name
- PDP1 (NCT04932434)
- Testing
- Psilocybin therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Joshua Woolley, MD, PhD
Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.
- Trial name
- NCT04433845
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sheppard Pratt Health System
Nicotine Dependence
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
One of the most promising lines of investigation for the therapeutic use of hallucinogens in the 1960s and 1970s was in the treatment of drug dependence.
- Trial name
- NCT01943994
- Testing
- Psilocybin-assisted treatment, Nicotine Replacement Therapy (NRT)
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Migraine Headache
Repeat Dosing of Psilocybin in Migraine Headache
In seeking to understand the capacity for psilocybin to reduce migraine headache burden, this study will investigate single and repeated dosing of psilocybin up to two doses.
- Trial name
- NCT04218539
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Yale University